- Globalization of infectious diseases due to climate change
- High reliance on royalty business
- Lower patent cliff risks
- Lack of human resources to realize transformation
- Loss of business opportunities as nothing is done in emerging countries
- Higher hurdles to drug discovery and lower research efficiency
- Decrease in productivity/outflow of human resources
- Contraction in market for infectious disease drugs as awareness of hygiene increases
- Collapse of existing business models through disruptive innovation
Shionogi & Co., Ltd.
Greenhouse gas emissions & sustainability report data
Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
Water Usage
1.4K thousand m3
FY2022
Energy Use
337.9K MWh
FY2022
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023-04 to 2024-03 | 72.0K t-CO2e/year (Scope 1 & 2 market-based) |
| 2022-04 to 2023-03 | 230.7K t-CO2e |
| 2022 | 103.8K tCO2e (2022) |
| 2019-04 to 2020-03 | 85.2K tCO2e/year (Scope 1+2 market-based) |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- FY2030: Reduce Scope 1+2 by 46.2% and Scope 3 Category 1 by 20% (relative to FY2019); FY2050: Achieve zero emissions
🎯 Climate & Sustainability Targets
📅 Medium-term
- FY2030: Reduce Scope 1+2 by 46.2% and Scope 3 Category 1 by 20% (relative to FY2019)
🔭 Long-term
- FY2050: Achieve zero emissions
🌱 ESG Focus Areas
Infectious DiseaseHuman ResourcesSupply Chain ManagementEnvironmental SustainabilityGovernance